ArticleRegenerative therapy2026
WTAP stabilizes MMP12 expression to promote the malignant phenotypes of esophageal cancer cells.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal cancer (EC) is a highly aggressive malignancy with a poor prognosis, largely due to its invasive nature and metabolic reprogramming. Matrix metalloproteinase 12 (MMP12) has been implicated in various cancers, but its specific regulatory mechanisms and functional impact on EC remain unclear. This study aimed to investigate the role of MMP12 in EC progression and its underlying regulatory mechanisms. Methods: The GSE161533 dataset was analyzed to identify differentially expressed genes (DEGs) between EC and normal tissues, with a focus on genes linked to apoptosis, proliferation, and glycolysis via the GeneCards database. Key signature genes were further screened using lasso regression, support vector machine (SVM), and random forest (RF) algorithms. Gene expression was validated by quantitative real-time polymerase chain reaction and Western blotting. Cell migration and invasion were analyzed by transwell assays. Cell proliferation was analyzed by 5-Ethynyl-2'-deoxyuridine assay. Cell apoptosis was assessed by flow cytometry. Glucose consumption, lactate production, and ATP levels were analyzed by commercial kits. Flow cytometry was used to quantify the number of clusters of differentiation 68 (CD68)-positive cells and CD206-positive macrophages. The interaction between MMP12 and WT1 associated protein (WTAP) was examined using methylated RNA immunoprecipitation (MeRIP) and RNA immunoprecipitation (RIP) assays. Results: MMP12 was identified as a key gene in EC tissues, and its expression was significantly upregulated in EC tissues and cells in comparison with normal samples. Knockdown of MMP12 suppressed migration, invasion, proliferation, and glycolysis while promoting apoptosis in KYSE150 and TE-10 cells. Additionally, MMP12 silencing inhibited M2 macrophage polarization. Mechanistically, WTAP stabilized MMP12 expression in an m6A-dependent manner. Further, silencing WTAP suppressed the malignant phenotypes of KYSE150 and TE-10 cells by downregulating MMP12 expression. Conclusion: WTAP stabilized MMP12 expression via m6A modification, thereby enhancing the malignant phenotypes of EC cells. Clinically, targeting the WTAP-MMP12 axis could represent a promising therapeutic strategy to inhibit EC progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.